Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2006-10-06

Last Posted Date: 2009-08-12

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 24

Registration Number: NCT00384280

A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis

Phase 3

Completed

Conditions: Tuberculosis

First Posted Date: 2006-04-24

Last Posted Date: 2010-08-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 6400

Registration Number: NCT00317330

Locations: 🇧🇷
Municipal Health Department, Rio de Janeiro, Brazil

Prediction of Drug Interactions With CYP2C9 Substrates

Not Applicable

Completed

Conditions: Healthy Volunteers

First Posted Date: 2005-09-27

Last Posted Date: 2008-10-29

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 16

Registration Number: NCT00226538

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms
Advanced Solid Tumors

Interventions: Drug: ixabepilone
Drug: Rifampin

First Posted Date: 2005-09-21

Last Posted Date: 2020-11-02

Lead Sponsor: R-Pharm

Target Recruit Count: 19

Registration Number: NCT00207090

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)

Phase 3

Completed

Conditions: Latent Tuberculosis Infection

Interventions: Drug: Rifampin
Drug: Isoniazid

First Posted Date: 2005-09-15

Last Posted Date: 2017-12-19

Lead Sponsor: McGill University

Target Recruit Count: 844

Registration Number: NCT00170209

Locations: 🇧🇷
Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde, Rio de Janeiro, Brazil
🇮🇩
Health Research Unit, Faculty of Medicine, Bandung, West Java, Indonesia
🇧🇯
Centre de Pneumophthysiologie, Cotonou, Benin

and more 6 locations

Tuberculosis Treatment Shortening Trial

Phase 3

Completed

Conditions: Tuberculosis

Interventions: Drug: Ethambutol
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Rifampin

First Posted Date: 2005-08-15

Last Posted Date: 2018-11-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 394

Registration Number: NCT00130247

Locations: 🇧🇷
Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
🇺🇬
Mulago Hospital Complex, Kampala, Uganda
🇵🇭
Makati Medical Center, Makati, National Capital Region, Philippines

Treatment of Latent TB Infection for Jailed Persons

Phase 3

Completed

Conditions: Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifampin

First Posted Date: 2005-08-09

Last Posted Date: 2020-07-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 364

Registration Number: NCT00128206

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness

Phase 2

Completed

Conditions: Onchocerciasis

First Posted Date: 2005-08-08

Last Posted Date: 2024-08-15

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 80

Registration Number: NCT00127504

Locations: 🇬🇹
Universidad del Valle/MERTU, Guatemala City, Guatemala

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

Not Applicable

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: Atazanavir
Drug: Rifampin
Drug: Ritonavir

First Posted Date: 2004-11-17

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00096850

Locations: 🇺🇸
Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States
🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸
Stanford CRS, Palo Alto, California, United States

Tuberculosis Prevention for HIV Infected Adults

Phase 3

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifampin
Drug: Rifapentine

First Posted Date: 2003-03-28

Last Posted Date: 2012-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1148

Registration Number: NCT00057122

Locations: 🇿🇦
Chris Hani Baragwanath Hospital, Soweto, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy